Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood in which the bone marrow overproduces monocytes and other myeloid cells. It usually appears before age four, is driven by mutations in the RAS signaling pathway, and is diagnosed with blood counts, a bone marrow exam, and genetic testing. For most children, a hematopoietic stem cell transplant is the only treatment that can cure it.
JMML sits in a small, unusual corner of pediatric oncology. It behaves partly like a chronic leukemia and partly like a bone marrow disorder, which is why the World Health Organization classifies it as a myelodysplastic/myeloproliferative neoplasm rather than as an acute leukemia. Below, I walk through what causes it, how doctors confirm it, and what treatment looks like for families.
What Is Juvenile Myelomonocytic Leukemia?
JMML is one of the rarer forms of childhood leukemia. It begins in a hematopoietic stem or progenitor cell, the parent cell that normally gives rise to all blood cells. A genetic change in that cell makes its descendants, especially monocytes, multiply without the usual brakes.
The disease is part of the broader family of myelomonocytic leukemias, but it is distinct from adult chronic myelomonocytic leukemia and from acute myelomonocytic leukemia. In JMML, blast cells (very immature cells) stay below 20% of the marrow, while mature and maturing monocytes pile up in the blood, spleen, liver, skin, and sometimes the lungs.
It also differs from the more familiar types described in our overview of the different types of childhood leukemia. Acute lymphoblastic leukemia is far more common in children; JMML accounts for only a small fraction of pediatric leukemias and is seen more often in boys than girls.
Causes and Risk Factors
JMML is a disease of the RAS/MAPK pathway, a chain of signaling proteins that tells blood cells when to grow. In nearly every child with JMML, a mutation switches this pathway permanently on. The genes involved are well defined:
| Gene | Type of change | Clinical notes |
|---|---|---|
| PTPN11 | Usually somatic (acquired in the leukemia cells) | The most frequently mutated gene; often an aggressive course |
| KRAS | Somatic | Often presents in infancy; may be associated with monosomy 7 |
| NRAS | Somatic | Variable course; a subset of children remain stable for long periods |
| NF1 | Germline (inherited or new), with a second hit in leukemia cells | Seen in children with neurofibromatosis type 1 |
| CBL | Germline, with loss of the normal copy in leukemia cells | Some cases regress without treatment |
Two inherited conditions raise the risk. Children with neurofibromatosis type 1 (NF1), who often have café-au-lait skin spots, carry an increased lifetime risk of JMML. Infants with Noonan syndrome can develop a JMML-like myeloproliferative disorder that frequently settles on its own, so these babies are usually watched closely rather than rushed to transplant.
Parents often ask whether something they did caused the disease. The answer is no. The somatic mutations arise by chance in a single cell, and no diet, vaccine, or environmental exposure has been shown to trigger JMML.
Signs and Symptoms
Symptoms come from two processes: the marrow is crowded by abnormal cells, and those cells spread into organs. Because the marrow is where most blood cells are made (see how the skeleton supports blood cell production), normal red cells and platelets fall as the disease advances.
- Enlarged spleen (splenomegaly), the most consistent finding, often with an enlarged liver
- Pallor and tiredness from anemia
- Easy bruising, nosebleeds, or tiny red skin spots from a low platelet count
- Fever, recurrent infections, and poor weight gain
- Swollen lymph nodes
- Skin rashes, including eczema-like patches or firm nodules
- Cough or rapid breathing when monocytes infiltrate the lungs
Many of these signs overlap with common childhood infections, which is why JMML can take time to recognize. A persistently large spleen combined with a high monocyte count is the pattern that should prompt referral to a pediatric hematologist.
How JMML Is Diagnosed
Diagnosis combines blood tests, a bone marrow examination, and molecular testing. The standard criteria require clinical and hematologic features plus a genetic or supporting finding.
Core clinical and blood findings
- Peripheral blood monocyte count of at least 1 × 10⁹/L (1,000 per microliter)
- Blasts below 20% in both blood and marrow
- Splenomegaly
- Absence of the BCR-ABL1 fusion gene, which rules out chronic myeloid leukemia
Genetic confirmation
A mutation in PTPN11, KRAS, NRAS, NF1, or CBL (or a clinical diagnosis of NF1) confirms the diagnosis. When none is found, doctors look for supporting features such as monosomy 7 on chromosome analysis, a fetal hemoglobin level that is high for the child’s age, immature myeloid cells in the blood, or marrow cells that are abnormally sensitive to the growth factor GM-CSF.
A bone marrow aspirate and biopsy show the cellularity of the marrow and the proportion of blasts. Our guide to the composition and function of bone marrow explains what the pathologist is looking at. Next-generation sequencing panels now identify the driver mutation in almost every case, and chromosome studies or FISH detect monosomy 7.
These tests also separate JMML from conditions that mimic it, such as viral infections (cytomegalovirus and Epstein-Barr virus can raise monocytes and enlarge the spleen), other forms of bone marrow failure, and immune disorders.
Treatment Options
Treatment depends on the underlying mutation and how quickly the disease is progressing. The goals are to control symptoms, prepare the child for transplant when needed, and avoid over-treating the forms that may regress.
Hematopoietic stem cell transplant
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only reliably curative treatment for most children with JMML, particularly those with PTPN11, KRAS, or NF1-associated disease. High-dose chemotherapy clears the marrow, and stem cells from a matched sibling, unrelated donor, or cord blood rebuild it. Relapse after transplant remains the main challenge, and some children are offered a second transplant.
Therapy before transplant
Children may receive low-intensity chemotherapy, or a hypomethylating drug such as azacitidine, to reduce the spleen size and white count while a donor is found. Removing the spleen is occasionally considered when it is massively enlarged, though practice varies between centers.
Watchful waiting
Children with Noonan syndrome, germline CBL mutations, and some with NRAS mutations may be monitored closely without immediate transplant, because their disease can stabilize or resolve.
Research directions
Targeted drugs that block the RAS pathway, such as MEK inhibitors, and epigenetic therapies are being studied in clinical trials. These are not yet standard care, but they reflect a shift toward matching treatment to each child’s specific mutation.
Outlook and Long-Term Follow-Up
Without transplant, most forms of JMML progress, and untreated disease can be fatal. With transplant, many children achieve long-term remission. Factors linked to a less favorable outlook include older age at diagnosis, a low platelet count, and a high fetal hemoglobin level.
Survivors need follow-up for transplant late effects, including growth, fertility, heart, and hormone function. Families navigating this may find our primer on hematological disorders for patients and caregivers useful, and our leukemia guide covers the wider picture.
Key Takeaways
- JMML is a rare leukemia of young children, usually diagnosed before age four.
- It is driven by mutations that activate the RAS/MAPK pathway, most often in PTPN11, KRAS, NRAS, NF1, or CBL.
- Diagnosis requires a monocyte count of at least 1 × 10⁹/L, blasts under 20%, splenomegaly, no BCR-ABL1, and a genetic or supporting finding.
- Stem cell transplant is the main curative treatment; some genetic subtypes can be watched.
- See a doctor if a young child has a persistently enlarged abdomen, unexplained bruising, pallor, or recurrent fevers.
Frequently Asked Questions
Is juvenile myelomonocytic leukemia hereditary?
Most cases are not inherited; the mutation arises by chance in the child’s blood cells. The exceptions are children with neurofibromatosis type 1, Noonan syndrome, or a germline CBL mutation, where a predisposing gene is present from birth. Genetic counseling can clarify the risk for siblings.
How is JMML different from adult chronic myelomonocytic leukemia?
Both involve excess monocytes, but JMML occurs in infants and toddlers and is almost always driven by RAS pathway mutations. Adult chronic myelomonocytic leukemia typically affects older adults and involves a broader range of genetic changes.
Can JMML go away without treatment?
In most children it does not. However, the JMML-like disorder in Noonan syndrome and some cases linked to germline CBL or NRAS mutations can improve spontaneously, which is why genetic testing shapes the treatment plan.
What is the recovery like after a stem cell transplant?
Children usually spend several weeks in hospital while the new marrow engrafts, followed by months of close outpatient monitoring for infection, graft-versus-host disease, and relapse. Long-term follow-up continues for years to track growth and development.
